Clinical therapeutic effects and challenges of GLP-1 receptor agonists The primary GLP-1RAs used worldwide as anti-obesity drugs are liraglutide (Saxenda, Novo Nordisk) as a once-daily subcutaneous injection and semaglutide (Wegovy, Novo Nordisk) as a once-weekly subcutaneous injection
3/ Do Zepbound and Wegovy have generic versions
[PubMed] [Google Scholar] 6.Lecane PS, Karaman MW, Sirisawad M, et al
Injectable BPC-157 is preferred for musculoskeletal injuries, as it allows targeted delivery to the affected area and higher systemic bioavailability
According to company disclaimer, patients typically experience "1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes." Results are not guaranteed
Carrier Letter 2023-01, entitled Prevention and Treatment of Obesity, provided a comprehensive set of recommendations for health plans: screening and prevention, anti-obesity medications, and bariatric/metabolic surgery